secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001193125-23-078511
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Intellia board member Caroline Dorsa to resign effective June 15, 2023
----------------------------------------------------------------------

- Caroline Dorsa resigned from Intellia board and all committees effective June 15, 2023.
- She served as Audit Committee Chair and on the Compensation and Talent Development Committee.
- Resignation follows her appointment as chair of Biogen's board; no disagreement with Intellia.
- Company thanked Dorsa for her long, dedicated service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523078511/0001193125-23-078511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523078511/d480012d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-078511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer